<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789826</url>
  </required_header>
  <id_info>
    <org_study_id>AssiutU4958</org_study_id>
    <nct_id>NCT02789826</nct_id>
  </id_info>
  <brief_title>Laparoscopic Versus Open Resection of Cancer Stomach</brief_title>
  <official_title>Laparoscopic Versus Open Resection of Cancer Stomach Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of surgical procedures for resection of cancer stomach is to resection of the tumor&#xD;
      mass with safety margin and its drainage lymph nodes (lymphadenectomy).&#xD;
&#xD;
      There are two main types of techniques (open &amp; laparoscopic) Many studies were done comparing&#xD;
      these two techniques showed that Laparoscopic resection is superior in early postoperative&#xD;
      recovery (less pain ,less bleeding and shorter hospital stay) but less radical than open&#xD;
      resection (less safety margin &amp; less lymphadenectomy) but because of the ongoing advances on&#xD;
      laparoscopic surgery these results needs more and more revision.&#xD;
&#xD;
      So the investigators conduct this randomized controlled trial aiming at comparing open and&#xD;
      laparoscopic resection of cancer stomach to choose the best surgical procedure for resection&#xD;
      of cancer stomach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The surgical procedure for resection of cancer stomach aiming at resection of the tumor mass&#xD;
      with safety margin and its drainage lymph nodes (lymphadenectomy).&#xD;
&#xD;
      # Tumor resection;&#xD;
&#xD;
      Will be done by one of the following techniques:&#xD;
&#xD;
        1. laparoscopic gastrectomy (totally laparoscopic, laparoscopy-assisted, and hand-assisted)&#xD;
           types of gastrectomy (according to site of tumour)&#xD;
&#xD;
        2. Open gastrectomy (according to the site of tumor). # Lymphadenectomy; Will be done&#xD;
           according to Japanese Gastric Cancer Association guidelines for optimal lymph node&#xD;
           dissection levels for Early Gastric Cancer (1):&#xD;
&#xD;
             -  D1+alpha -(perigastric lymph node dissection) for mucosal cancer, for which EMR is&#xD;
                not indicated and for histologically differentiated submucosal cancer of &lt; 1.5 cm&#xD;
                in diameter;&#xD;
&#xD;
             -  D1+ beta for preoperatively diagnosed submucosal cancer without lymph node&#xD;
                metastasis (N0), for which D1+ alpha is not indicated, and for early cancer &lt; 2.0&#xD;
                cm in diameter with only perigastric lymph node metastasis (N1);&#xD;
&#xD;
             -  D2 for early cancer &gt; 2.0 cm in diameter. Follow up: all patients will be followed&#xD;
                up clinically for the outcomes for each surgical technique.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Laparoscopic gastric cancer resection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of lymph nodes in the postoperative spicement.</measure>
    <time_frame>two weeks</time_frame>
    <description>considered a prognostic factor for disease-free postoperative survival The more the number of lymph nodes the more radicality of the procesure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days post-operative</time_frame>
    <description>Measured as 30-day mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>Postoperatively with follow-up to one year</time_frame>
    <description>Complications will be graded according to the Clavien-Dindo classification, which grades complications with regard to necessary treatment for this complication. Also Long-term complications, such as hernia cicatricialis will be monitored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative blood loss</measure>
    <time_frame>during surgery, 1 day</time_frame>
    <description>Laparoscopic gastrectomy is associated with less peri-operative blood loss. Blood loss will be measured in milliliters and compared to the conventional 'open' group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Surgery</measure>
    <time_frame>Peri-operatively, 1 day</time_frame>
    <description>UsuallyLaparoscopic gastrectomy takes longer time to complete. The duration of the procedure will be registered in minutes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Laparoscopic gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to the 'laparoscopic Gastrectomy' group will undergo laparoscopic gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to the 'Open Gastrectomy' group will receive gastrectomy via laparotomy. This group is considered the control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic gastrectomy</intervention_name>
    <description>Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.</description>
    <arm_group_label>Laparoscopic gastrectomy</arm_group_label>
    <other_name>Minimally invasive gastrectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open gastrectomy</intervention_name>
    <description>patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy</description>
    <arm_group_label>Open gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with primary carcinoma of the stomach, where the tumor is considered&#xD;
             surgically resectable (T1-3, N0-1, M0).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Infiltration to the( pancreas ,liver ,colon or vital vascular structure).&#xD;
&#xD;
          -  Metastasis to the (liver, lung, brain, paraaortic LN involvement).&#xD;
&#xD;
          -  Peritoneal deposit.&#xD;
&#xD;
          -  Surgically unfit patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mostafa A Hamad, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University- Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mostafa M Sayed</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University- Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed G Taher</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University- Faculty of Medicine- General surgery department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospitals</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 22, 2016</study_first_submitted>
  <study_first_submitted_qc>May 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>September 6, 2020</last_update_submitted>
  <last_update_submitted_qc>September 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed Gamal Ameen Taher</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

